Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : EntreMed (ENMD) -- Ignore unavailable to you. Want to Upgrade?

To: billkirn who wrote (614)	5/5/1998 3:12:00 AM
From: StockDoc	Read Replies (2) \| Respond to of 2135

Other cancer drugs in discovery, clinical trial or market phase, including AGPH's MMP inhibitor, do not ENTIRELY block tumor growth, and do not eradicate advanced cancer (i.e, > 5% body weight tumor mass) in mice. IF (!) ES/AS combo can do this in people, AND it can be manufactured at acceptable cost and in sufficient quantities, AND no similarly efficacious and safe drug appears on the horizon, ALL the others (cancer drugs, companies, revenues, stock) will be eliminated. At once. Those who fall will include the "almost as good as ES/AS angiogenesis inhbitors", even ENMD's other project, thalidomide. The best treatment beats the others and takes over the market in the cancer business. Sorry. StockDoc